CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 858.00 thousand shares for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-27 was 858.00K shares, a 23.94% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-28 was 615.00K shares, a 35.80% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-27 was 1.13M shares, a 51.61% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-28 was 1.13M shares, a 122.92% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 918.00K shares, a 73.21% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 530.00K shares, a 18.71% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 652.00K shares, a 16.43% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 560.00K shares, a 268.42% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-27 | 858.00K shares 10-Q · filed 2026-08-05 | 637.00K shares 10-Q · filed 2026-08-05 | ||
| 2026-03-28 | 615.00K shares 10-Q · filed 2026-05-07 | |||
| 2025-12-27 | 918.00K shares 10-K · filed 2026-02-18 | |||
| 2025-09-27 | 1.13M shares 10-Q · filed 2025-11-05 | 1.06M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-28 | 1.13M shares 10-Q · filed 2026-08-05 | 1.00M shares 10-Q · filed 2026-08-05 | ||
| 2025-03-29 | 958.00K shares 10-Q · filed 2026-05-07 | |||
| 2024-12-28 | 530.00K shares 10-K · filed 2026-02-18 | |||
| 2024-09-28 | 746.00K shares 10-Q · filed 2025-11-05 | 505.00K shares 10-Q · filed 2025-11-05 | ||
| 2024-06-29 | 506.00K shares 10-Q · filed 2025-08-06 | 482.00K shares 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | 448.00K shares 10-Q · filed 2025-05-07 | |||
| 2023-12-30 | 652.00K shares 10-K · filed 2026-02-18 | |||
| 2023-09-30 | 588.00K shares 10-Q · filed 2024-11-06 | 514.00K shares 10-Q · filed 2024-11-06 | ||
| 2023-07-01 | 594.00K shares 10-Q · filed 2024-08-07 | 589.00K shares 10-Q · filed 2024-08-07 | ||
| 2023-04-01 | 405.00K shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 560.00K shares 10-K · filed 2025-02-19 | |||
| 2022-09-24 | 571.00K shares 10-Q · filed 2023-11-08 | 568.00K shares 10-Q · filed 2023-11-08 | ||
| 2022-06-25 | 597.00K shares 10-Q · filed 2023-08-09 | 550.00K shares 10-Q · filed 2023-08-09 | ||
| 2022-03-26 | 152.00K shares 10-Q · filed 2023-05-11 | |||
| 2021-12-25 | 152.00K shares 10-K · filed 2024-02-14 | |||
| 2021-09-25 | 154.00K shares 10-Q · filed 2022-11-02 | 158.00K shares 10-Q · filed 2022-11-02 | ||
| 2021-06-26 | 159.00K shares 10-Q · filed 2022-08-03 | 159.00K shares 10-Q · filed 2022-08-03 | ||
| 2020-12-26 | 249.00K shares 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |